AU2001250557A1 - Crystal - Google Patents

Crystal

Info

Publication number
AU2001250557A1
AU2001250557A1 AU2001250557A AU5055701A AU2001250557A1 AU 2001250557 A1 AU2001250557 A1 AU 2001250557A1 AU 2001250557 A AU2001250557 A AU 2001250557A AU 5055701 A AU5055701 A AU 5055701A AU 2001250557 A1 AU2001250557 A1 AU 2001250557A1
Authority
AU
Australia
Prior art keywords
lbd
har
ligand binding
hpr
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001250557A
Inventor
Maria Armenia Carrondo
Peter Donner
Ursula Egner
Pedro M. Matias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2001250557A1 publication Critical patent/AU2001250557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

A crystal comprising an androgen receptor ligand binding domain (AR-LBD) is provided. The crystal structures of the human Androgen Receptor Ligand Binding Domain (hAR-LBD) in comparison with the human Progesterone Receptor Ligand Binding Domains (hPR-(hPR-LBD) complexed with the same ligand metribolone (R1881) are also provided. The three-dimensional structures of the hAR LBD as well as the hPR LBD show the typical nuclear receptor fold. The change of two residues in the ligand binding pocket (LBP) between hPR and hAR seems to be the most likely source for the specificity of the R1881 ligand binding to hAR LBD. The structural implications of the 14 known mutations in the LBP of the hAR LBD associated with either prostate cancer (PC) or the partial androgen receptor insensitivity syndrome (PAIS) or complete androgen receptor insensitivity syndrome (CAIS) are analysed. The effects of most of these mutants may be explained on the basis of the crystal structure.
AU2001250557A 2000-03-09 2001-03-09 Crystal Abandoned AU2001250557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005689 2000-03-09
GBGB0005689.5A GB0005689D0 (en) 2000-03-09 2000-03-09 Crystal
PCT/IB2001/000475 WO2001066599A1 (en) 2000-03-09 2001-03-09 Crystal

Publications (1)

Publication Number Publication Date
AU2001250557A1 true AU2001250557A1 (en) 2001-09-17

Family

ID=9887287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001250557A Abandoned AU2001250557A1 (en) 2000-03-09 2001-03-09 Crystal

Country Status (9)

Country Link
US (1) US20030167999A1 (en)
EP (1) EP1265927B1 (en)
JP (1) JP2003525948A (en)
AT (1) ATE430163T1 (en)
AU (1) AU2001250557A1 (en)
DE (1) DE60138532D1 (en)
ES (1) ES2326516T3 (en)
GB (2) GB0005689D0 (en)
WO (1) WO2001066599A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235367B2 (en) * 2000-07-12 2007-06-26 Genetics Institute, Llc. Method using crystal structure of estrogen receptor-β complex
JP4447826B2 (en) * 2002-06-03 2010-04-07 武田薬品工業株式会社 Mutant androgen receptor, cancer cells expressing the same, methods for producing them, and uses thereof
WO2006117592A1 (en) * 2005-04-29 2006-11-09 Inserm Methods of modulating nuclear receptors
EA035535B1 (en) * 2012-07-27 2020-07-01 Арагон Фармасьютикалз, Инк. Fusion protein and device for treating diseases or conditions related to androgen receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6236946B1 (en) * 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
WO2001027622A1 (en) * 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain

Also Published As

Publication number Publication date
US20030167999A1 (en) 2003-09-11
WO2001066599A1 (en) 2001-09-13
GB0214799D0 (en) 2002-08-07
GB0005689D0 (en) 2000-05-03
EP1265927A1 (en) 2002-12-18
ES2326516T3 (en) 2009-10-14
GB2373505A (en) 2002-09-25
JP2003525948A (en) 2003-09-02
EP1265927B1 (en) 2009-04-29
ATE430163T1 (en) 2009-05-15
DE60138532D1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
CA2141826A1 (en) Starches Modified with Amino-Multicarboxylates
AU2561799A (en) Radiotelephone adapted to the identity of its user
BR9909860A (en) Specific cd19xcd3 polypeptides and their uses
EP1024146A4 (en) The use of steroid saponin compounds to prevent senility, and novel steroid saponin compounds
WO1999026966A3 (en) Nuclear receptor ligands and ligand binding domains
NO20031350D0 (en) Electromagnetic resistivity instrument with the ability to look ahead
BR0009421A (en) Inhibitors of lfa-1 binding to and use of icams
AU2001250557A1 (en) Crystal
AU7686100A (en) Template molecule having broad applicability and highly efficient function meansof cell-free synthesis of proteins by using the same
AU2001234986A1 (en) Online business directory with thesaurus and search template
Hammond The miniature votive vessels from the Sanctuary of Athena Alea at Tegea
AMIR et al. Cytotoxic activity of Thymus vulgaris, Achillea millefolium and Thuja orientalison different growing cell lines
WO2002092029A3 (en) Cosmetic and dermatological preparations for removing and regulating sebum
Wallace et al. Towards a new partnership: the EC and EFTA in the wider Western Europe
CA2070799A1 (en) Thioxanthenone antitumor agents
JP2000509064A5 (en)
Wijkman Policy options facing EFTA
Kwon The Functional Features of the Progressive
CA2158678A1 (en) Use of 5-Thia-1, 4-Diazabicyclo/4.2.0/Octane-3,8-Dioxo Compounds in Antitumor Therapy
Barazangi Dauna Natakalam: Mufakirat Amrikiyat Yaftahn Nawafidh al ImanAlaAlam Mutagheyr
Wang et al. Experiments and calculations of the 100 kHz sky-wave
Kleimenova et al. Pi1C geomagnetic pulsations in the region of the eastern electrojet
Morris Regional Disparities and Policy in Modern Argentina
Moock Panel on the characteristics of women as users of technology
WO2003074128A3 (en) Atomic structure of the hemalbumin complex and its use in designing therapeutic compounds